Alexandria, VA – In a milestone decision, the U.S. Food and Drug Administration (FDA) announced November 10 that it is recommending the removal of black-box warnings, the agency’s highest warning for prescription medications, from all hormone therapies used to treat symptoms from menopause and perimenopause.

“This is a huge win for women,” said Adrian Thompson, a local physician assistant specializing in women’s healthcare. “This finally allows for more open, informed conversations about hormone therapy. Breast cancer survivorship is about so much more than just surviving ,” she added. “It’s about quality of life.”

Even as up to 90 percent of these survivors develop sexual health problems, however, often due to treatment-induced menopause, most are told that estrogen and other hormone

See Full Page